In the news

News headlines are articles that reference ResMed's company, people, or business practices.

Advanced Search
  • May 21, 2017
    MedPage Today

    Patients with persistent hypercapnia following an acute exacerbation of chronic obstructive pulmonary disease (COPD) had a longer time to death or rehospitalization if non-interventional ventilation was added to their home oxygen therapy, researchers found.

  • May 16, 2017
    Sleep Review

    ResMed Inc announced that people with obstructive sleep apnea who develop central sleep apnea (CSA) are more compliant on therapy after they switch from continuous positive airway pressure (CPAP) therapy to adaptive servo-ventilation (ASV) therapy, according to the largest-ever analysis of patients with treatment-emergent CSA.

  • May 8, 2017
    Becker's Hospital Review

    Amy Cook, Director of Healthcare Informatics at ResMed, was named to Becker's list of 110 Women in Medtech to Know in 2017. Joining ResMed in 2012, she was integral in developing and rolling out the company's suite of connected health IT services and platforms.

  • Medgadget logo
    May 3, 2017
    Medgadget

    The S+ platform is the newest technology disrupting the $60B consumer sleep industry. Developed by SleepScore Labs, a joint venture between ResMed, a 25-year leader in prescription sleep medical devices, Dr. Mehmet Oz, and Pegasus Capital Advisors, the S+ is a clinical grade, non-prescription, non-contact sleep monitoring device coupled with a mobile app.

  • San Diego Union-Tribune logo
    April 25, 2017
    San Diego Union-Tribune

    Instead of packing up their larger, bedside machines from home for a trip, sleep apnea patients can travel with a much smaller device, according to the company. It’s akin to taking a tablet on the road while leaving the desktop computer at home, said ResMed Chief Executive Michael “Mick” Farrell.

  • Xconomy logo
    April 25, 2017
    Xconomy

    The debut of ResMed’s AirMini is only part of a bigger picture, according to Jim Hollingshead, ResMed’s president of the Americas. Hollingshead said the AirMini is part of a strategic shift that began four or five years ago, when ResMed began to pivot from developing medtech hardware to becoming a provider of “connected healthcare.”

  • HME Business
    April 13, 2017
    HME Business

    Individuals with obstructive sleep apnea who develop central sleep apnea (CSA) are more compliant with their therapy after switching from continuous positive airway pressure (CPAP) therapy to adaptive servo-ventilation (ASV) therapy, according to a broad survey of sleep patients patients with treatment-emergent CSA that was commissioned by sleep equipment maker ResMed.

  • FeibusTech
    April 10, 2017
    FeibusTech

    Mike Feibus tries S+, the world's first non-contact sleep tracker, discusses what it does, what it has, and more.

  • ATS logo
    April 4, 2017
    American Thoracic Society

    The American Thoracic Society today announced a new $100,000 two-year research fellowship funded by ResMed in the area of noninvasive ventilation (NIV) in chronic obstructive pulmonary disease (COPD).

  • March 23, 2017
    Mergers & Acquisitions

    “Brightree was an important and immediately accretive strategic acquisition for ResMed. It exemplified a double-down on our ongoing investments to leverage connected care and digital health, and to change the basis of competition in our industry,” ResMed CEO Mick Farrell told Mergers & Acquisitions in a March 2017 interview. “One year from announcing the acquisition, we can reaffirm our goals going in: Brightree represents a big step forward for ResMed, fulfilling our role as the world’s leading tech-driven medical device company, liberating data and unlocking incredible value for our customers.”

Show 5102550100 per page
Media contacts - Bottom Blue - All Interior Pages

Media contact

Jayme Rubenstein
(858) 836-6798

news@resmed.com

 

Receive ResMed news releases when they publish.

Subscribe

ResMed provides a non-transferable, non-exclusive license to the copyrighted images, drawings and materials subject to the following Terms of Use.

All countries & languages